Recently, the FDA approved the HIF-2α inhibitor belzutifan for treating certain cancers associated with von Hippel–Lindau disease, such as renal cell carcinoma, hemangioblastoma, and pancreatic neuroendocrine tumors [164]. This evidence concerns the gene EPAS1 and hereditary clear cell renal cell carcinoma.